malignant tumor
Conditions
Interventions
case series:none
Sponsors
Ziyang Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Age >= 18 years old, gender not limited; Pathologically or clinically diagnosed as a malignant tumor, suitable for and first-time use of immune checkpoint inhibitors (PD1/PD-L1); Physical fitness ECOG <= 1 point; Understand and sign the informed consent form.
Exclusion criteria
Exclusion criteria: Known severe allergy to the study drug or any of its excipients; Conditions that are not suitable for ICIs treatment as specified in the 2023 version of the CSCO Guidelines for Immune Checkpoint Inhibitors. Activity or history of autoimmune disease or immunodeficiency; Treatment with systemic immunostimulants; Subjects deemed by the investigator to be unsuitable for ICIs treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity; | — |
Countries
China
Contacts
Public ContactJieyan Luo
Ziyang Central Hospital
Outcome results
None listed